Noninvasive biomarkers for the diagnosis of steatohepatitis and advanced fibrosis in NAFLD

Biomarker Research

Volumn 1, Issue 1, 2013, Pages

  Pearce, Steven G ^a   Thosani, Nirav C ^a   Pan, Jen Jung ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Biomarker; Fibrosis; NAFLD; NASH; Noninvasive

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA 2 MACROGLOBULIN; APOLIPOPROTEIN A1; BILIRUBIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; FERRITIN; GAMMA GLUTAMYLTRANSFERASE; HAPTOGLOBIN; INTERLEUKIN 6; PENTRAXIN 3; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; ECHOGRAPHY; EXTRACELLULAR MATRIX; HUMAN; INFLAMMATION; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; MORBIDITY; MORTALITY; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; SLEEP DISORDERED BREATHING; TREATMENT RESPONSE;

EID: 84885166200     PISSN: None     EISSN: 20507771     Source Type: Journal    
DOI: 10.1186/2050-7771-1-7     Document Type: Review

References (77)

1. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002, 346:1221-1231. 10.1056/NEJMra011775, 11961152.
2. Wieckowska A, Feldstein AE. Nonalcoholic fatty liver disease in the pediatric population: a review. Curr Opin Pediatr 2005, 17:636-641. 10.1097/01.mop.0000172816.79637.c5, 16160540.
3. Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, Kechagias S. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006, 44:865-873. 10.1002/hep.21327, 17006923.
4. Xie L, Yui J, Hatori A, Yamasaki T, Kumata K, Wakizaka H, Yoshida Y, Fujinaga M, Kawamura K, Zhang MR. Translocator protein (18 kDa), a potential molecular imaging biomarker for non-invasively distinguishing non-alcoholic fatty liver disease. J Hepatol 2012, 57:1076-1082. 10.1016/j.jhep.2012.07.002, 22796156.
5. Soderberg C, Stal P, Askling J, Glaumann H, Lindberg G, Marmur J, Hultcrantz R. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 2010, 51:595-602. 10.1002/hep.23314, 20014114.
6. Wieckowska A, McCullough AJ, Feldstein AE. Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. Hepatology 2007, 46:582-589. 10.1002/hep.21768, 17661414.
7. Browning JD, Szczpaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, Hobbs HH. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004, 40:1387-1395. 10.1002/hep.20466, 15565570.
8. Sorrentino P, Tarantino G, Conca P, Perrella A, Terracciano ML, Vecchione R, Gargiulo G, Gennarelli N, Lobello R. Silent non-alcoholic fatty liver disease-a clinical-histological study. J Hepatol 2004, 41:751-757. 10.1016/j.jhep.2004.07.010, 15519647.
9. Mofrad P, Contos MJ, Haque M, Sargeant C, Fisher RA, Luketic VA, Sterling RK, Shiffman ML, Stravitz RT, Sanyal AJ. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 2003, 37:1286-1292. 10.1053/jhep.2003.50229, 12774006.
10. de Alwis NM, Day CP. Non-alcoholic fatty liver disease: the mist gradually clears. J Hepatol 2008, 48(Suppl 1):S104-S112.
11. Romeo GR, Lee J, Shoelson SE. Metabolic syndrome, insulin resistance, and roles of inflammation - mechanisms and therapeutic target. Arterioscler Thromb Vasc Biol 2012, 32:1771-1776. 10.1161/ATVBAHA.111.241869, 22815343.
12. Kleiner DE, Brunt EM, Natta MV, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, Yeh M, McCullough AJ, Sanyal A. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005, 41:1313-1321. 10.1002/hep.20701, 15915461.
13. Hotamisligil GS, Budavari A, Murray D, Spiegelman BM. Reduced tyrosine kinase activity of the insulin receptor in obesity-diabebes. J Clin Invest 1994, 94:1543-1549. 10.1172/JCI117495, 295304, 7523453.
14. Abiru S, Migita K, Maeda Y, Daikoku M, Ito M, Ohata K, Nagaoka S, Matsumoto T, Takii Y, Kusumoto K, Nakamura M, Komori A, Yano K, Yatsuhashi H, Eguchi K, Ishibashi H. Serum cytokine and soluble cytokine receptor levels in patients with non-alcoholic steatohepatitis. Liver Int 2006, 26:39-45. 10.1111/j.1478-3231.2005.01191.x, 16420507.
15. Alaaeddine N, Sidaoui J, Hilal G, Serhal R, Abedelrahman A, Khoury S. TNF-alpha messenger ribonucleic acid (mRNA) in patients with nonalcoholic steatohepatitis. Eur Cytokine Netw 2012, 23:107-111.
16. Satapathy SK, Garg S, Chauhan R, Sakhuja P, Malhotra V, Sharma BC, Sarin SK. Beneficial effects of tumor necrosis factor-alpha inhibition by pentoxyfilline on clinical, biochemical, and metabolic parameters of patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2004, 99:1946-1952. 10.1111/j.1572-0241.2004.40220.x, 15447754.
17. Satapathy SK, Sakhuja P, Malhotra V, Shamrma BC, Sarin SK. Beneficial effects of pentoxyfilline on hepatic steatosis, fibrosis and necroinflammation in patients with non-alcoholic steatohepatitis. J Gastroenterol Hepatol 2007, 22:634-638.
18. Zein CO, Yerian LM, Gogate P, Lopez R, Kirwan JP, Feldstein AE, McCullough AJ. Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial. Hepatology 2011, 54:1610-1619. 10.1002/hep.24544, 3205292, 21748765.
19. Senn JJ, Klover PJ, Nowak IA, Zimmers TA, Koniaris LG, Furlanetto RW, Mooney RA. Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatolocytes. J Biol Chem 2003, 278:13740-13746. 10.1074/jbc.M210689200, 12560330.
20. Kugelmas M, Hill DB, Vivian B, Marsano L, McClain CJ. Cytokines and NASH: pilot study of the effects of lifestyle modification and vitamin E. Hepatology 2003, 38:413-419.
21. Garcia-Galiano D, Sanchez-Garrido MA, Espejo I, Montero JL, Costan G, Marchal T, Membrives A, Gallardo-Valverde JM, Munoz-Castaneda JR, Arevalo De la Mata M, Muntane J. IL-6 and IGF-1 are independent prognostic factors of liver steatosis and non-alcoholic steatohepatitis in morbidly obese patients. Obes Surg 2007, 17:493-503. 10.1007/s11695-007-9087-1, 17608262.
22. Tarantino G, Conca P, Pasanisi F, Ariello M, Mastrolia M, Arena A, Tarantino M, Scopacasa F, Vecchione R. Could inflammatory markers help diagnose nonalcoholic steatohepatitis?. Eur J Gastroenterol Hepatol 2009, 21:504-511. 10.1097/MEG.0b013e3283229b40, 19318968.
23. Park SH, Kim BI, Yun JW, Kim JW, Park DI, Cho YK, Sung IK, Park CY, Sohn CI, Jeon WK, Kim H, Rhee EJ, Lee WY, Kim SW. Insulin resistance and c-reactive protein as independent risk factors for non-alcoholic fatty liver disease in non-obese Asian men. J Gastroenterol Hepatol 2004, 19:694-698. 10.1111/j.1440-1746.2004.03362.x, 15151626.
24. Yoneda M, Mawatari H, Fujita K, Iida H, Yonemitsu K, Kato S, Takahashi H, Kirikoshi H, Inamori M, Nozaki Y, Abe Y, Kubota K, Saito S, Iwasaki T, Terauchi Y, Togo S, Maeyama S, Nakajima A. High-sensitivity c-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH. J Gastroenterol 2007, 42:573-582. 10.1007/s00535-007-2060-x, 17653654.
25. Fierbinteanu-Braticevici C, Baicus C, Tribus L, Papacocea R. Predictive factors for nonalcoholic steatohepatitis (NASH) in patients with nonalcoholic fatty liver disease (NAFLD). J Gastrointestin Liver Dis 2011, 20:153-159.
26. Koruk M, Taysi S, Savas MC, Yilmaz O, Akcay F, Karakok M. Serum levels of acute phase proteins in patients with nonalcoholic steatohepatitis. Turk J Gastroenterol 2003, 14:12-17.
27. Hui JM, Farrell GC, Kench JG, George J. High sensitivity c-reactive protein values do not reliably predict the severity of histological changes in NAFLD. Hepatology 2004, 39:1458-1459. 10.1002/hep.20223, 15122781.
28. Zimmermann E, Anty R, Tordjman J, Verrijken A, Gual P, Tran A, Iannelli A, Gugenheim J, Bedossa P, Francque S, Marchand-Brustel YL, Clement K, Gaal LV, Sorensen T, Jess T. C-reactive protein levels in relation to various features of non-alcoholic fatty liver disease among obese patients. J Hepatol 2011, 55:660-665. 10.1016/j.jhep.2010.12.017, 21238518.
29. Yoneda M, Uchiyama T, Kato S, Endo H, Fujita K, Yoneda K, Mawatari H, Ijda H, Takahashi H, Kirikoshi H, Inamori M, Nozaki Y, Kobayashi N, Kubota K, Saito S, Maeyama S, Saraga M, Aburatani H, Kodama T, Nakajima A. Plasma pentraxin3 is a novel marker for nonalcoholic steatohepatitis. BMC Gastroenterol 2008, 8:53. 10.1186/1471-230X-8-53, 2621235, 19014569.
30. Fargion S, Mattioli M, Fracanzani AL, Sampietro M, Tavazzi D, Fociani P, Taioli E, Valenti L, Fiorelli G. Hyperferritinemia, iron overload, and multiple metabolic alterations identify patients at risk for nonalcoholic steatohepatitis. Am J Gastroenterol 2001, 96:2448-2455. 10.1111/j.1572-0241.2001.04052.x, 11513189.
31. Yoneda M, Nozaki Y, Endo H, Mawatari H, Iida H, Fujita K, Yoneda K, Takahashi H, Kirikoshi H, Inamori M, Kobayashi N, Kubota K, Saito S, Maeyama S, Hotta K, Nakajima A. Serum ferritin is a clinical biomarker in Japanese patients with nonalcoholic steatohepatitis (NASH) independent of HFE gene mutation. Dig Dis Sci 2010, 55:808-814. 10.1007/s10620-009-0771-y, 19267193.
32. Manousou P, Kalambokis G, Grillo F, Watkins J, Xirouchakis E, Pleguezuelo M, Leandro G, Arvaniti V, Germani G, Patch D, Calvaruso V, Mikhailidis DP, Dhillon AP, Burroughs AK. Serum ferritin is a discriminant marker for both fibrosis and inflammation in histologically proven non-alcoholic fatty liver disease patients. Liver Int 2011, 31:730-739. 10.1111/j.1478-3231.2011.02488.x, 21457446.
33. Kowdley KV, Belt P, Wilson LA, Yeh MM, Neuschwander-Tetri BA, Chalasani N, Sanyal AJ, Nelson JE. Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 2012, 55:77-85. 10.1002/hep.24706, 3245347, 21953442.
34. Chandok N, Minuk G, Wengiel M, Uhanova J. Serum ferritin levels do not predict the stage of underlying non-alcoholic fatty liver disease. J Gastrointestin Liver Dis 2012, 21:53-58.
35. Sakugawa H, Nakayoshi T, Kobashigawa K, Yamashiro T, Maeshiro T, Miyagi S, Shiroma J, Toyama A, Nakayoshi T, Kinjo F, Saito A. Clinical usefulness of biochemical markers of liver fibrosis in patients with nonalcoholic fatty liver disease. World J Gastroenterol 2005, 11:255-259.
36. Lydatakis H, Hager IP, Kostadelou E, Mpousmpoulas S, Pappas S, Diamantis I. Non-invasive markers to predict the liver fibrosis in non-alcoholic fatty liver disease. Liver Int 2006, 26:864-871. 10.1111/j.1478-3231.2006.01312.x, 16911470.
37. Malik R, Chang M, Bhaskar K, Nasser I, Curry M, Schuppan D, Byrnes V, Afdhal N. The clinical utility of biomarkers and the nonalcoholic steatohepatitis CRN liver biopsy scoring system in patients with nonalcoholic fatty liver disease. J Gastroenterol Hepatol 2009, 24:564-568. 10.1111/j.1440-1746.2008.05731.x, 19378390.
38. Tanwar S, Trembling PM, Guha IN, Parkes J, Kaye P, Burt AD, Ryder SD, Aithal GP, Day CP, Rosenberg WM. Validation of PIIINP for the detection and assessment of non-alcoholic steatohepatitis in patients with non-alcoholic fatty liver disease. Hepatology 2012, [Epub ahead of print].
39. Feldstein AE, Canbay A, Angulo P, Taniai M, Burgart LJ, Lindor KD, Gores GJ. Hepatocyte apoptosis and Fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 2003, 125:437-443. 10.1016/S0016-5085(03)00907-7, 12891546.
40. Feldstein AE, Gores GJ. Apoptosis in alcoholic and nonalcoholic steatohepatitis. Front Biosci 2005, 10:3093-3099. 10.2741/1765, 15970563.
41. Wieckowska A, Zein NN, Yerian LM, Lopez AR, McCullough AJ, Feldstein AE. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology 2006, 44:27-33.
42. Feldstein AE, Wieckowska A, Lopez AR, Liu YC, Zein NN, McCullough AJ. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology 2009, 50:1072-1078. 10.1002/hep.23050, 2757511, 19585618.
43. Papatheodoridis GV, Hadziyannis E, Tsochatzis E, Georgiou A, Kafiri G, Tiniakos DG, Margariti K, Manolakopoulos S, Manesis EK, Archimandritis AJ. Serum apoptotic caspase activity in chronic hepatitis C and nonalcoholic fatty liver disease. J Clin Gastroenterol 2010, 44:e87-e95. 10.1097/MCG.0b013e3181c0945a, 19881359.
44. Tsutsui M, Tanaka N, Kawakubo M, Sheena Y, Horiuchi A, Komatsu M, Nagaya T, Joshita S, Umemura T, Ichijo T, Matsumoto A, Yoshizawa K, Aoyama T, Tanaka E, Sano K. Serum fragmented cytokeratin 18 levels reflect the histologic activity score of nonalcoholic fatty liver disease more accurately than serum alanine aminotransferase levels. J Clin Gastroenterol 2010, 44:440-447.
45. Yilmaz Y, Dolar E, Ulukaya E, Akgoz S, Keskin M, Kiyici M, Aker S, Yilmaztepe A, Gurel S, Gulten M, Nak SG. Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis. World J Gastroenterol 2007, 13:837-844.
46. Shen J, Chan HL, Wong GL, Choi PC, Chan AW, Chan HY, Chim AM, Yeung DK, Chan FK, Woo J, Yu J, Chu WC, Wong VW. Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum biomarkers. J Hepatol 2012, 56:1363-1370. 10.1016/j.jhep.2011.12.025, 22314419.
47. Joka D, Wahl K, Moeller S, Schlue J, Vaske B, Bahr MJ, Manns MP, Schulze-Osthoff K, Bantel H. Prospective biopsy-controlled evaluation of cell death biomarkers for prediction of liver fibrosis and nonalcoholic steatohepatitis. Hepatology 2012, 55:455-464. 10.1002/hep.24734, 21993925.
48. Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001, 121:91-100. 10.1053/gast.2001.25540, 11438497.
49. Palekar NA, Naus R, Larson SP, Ward J, Harrison SA. Clinical model for distinguishing nonalcoholic steatohepatitis from simple steatosis in patients with nonalcoholic fatty liver disease. Liver Int 2006, 26:151-156. 10.1111/j.1478-3231.2005.01209.x, 16448452.
50. Poynard T, Ratziu V, Charlotte F, Messous D, Munteanu M, Imbert-Bismut F, Massard J, Bonyhay L, Tahiri M, Thabut D, Cadranel JF, Le Bail B, de Ledinghen V. LIDO Study Group CYTOL study group Diagnostic value of biochemical markers (NashTest) for the prediction of nonalcoholic steatohepatitis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol 2006, 6:34. 10.1186/1471-230X-6-34, 1657015, 17096854, LIDO Study Group CYTOL study group.
51. Gholam PM, Flancbaum L, Machan JT, Charney DA, Kotler DP. Nonalcoholic fatty liver disease in severely obese subjects. Am J Gastroenterol 2007, 102:399-408. 10.1111/j.1572-0241.2006.01041.x, 17311652.
52. Campos GM, Bambha K, Vittinghoff E, Rabl C, Posselt AM, Ciovica R, Tiwari U, Ferrel L, Pabst M, Bass NM, Merriman RB. A clinical scoring system for predicting nonalcoholic steatohepatitis in morbidly obese patients. Hepatology 2008, 47:1916-1923. 10.1002/hep.22241, 18433022.
53. Ulitsky A, Ananthakrishnan AN, Komorowski R, Wallace J, Surapaneni SN, Franco J, Saeian K, Gawrieh S. A noninvasive clinical scoring model predicts risk of nonalcoholic steatohepatitis in morbidly obese patients. Obes Surg 2010, 20:685-691. 10.1007/s11695-010-0118-y, 20336392.
54. Shimada M, Kawahara H, Ozaki K, Fukura M, Yano H, Tsuchishima M, Tsutsumi M, Takase S. Usefulness of a combined evaluation of the serum adiponectin level, HOMA-IR, and serum type IV collage 7S level to predict the early stage of nonalcoholic steatohepatitis. Am J Gastroenterol 2007, 102:1931-1938. 10.1111/j.1572-0241.2007.01322.x, 17511754.
55. Deng Y, Scherer PE. Adipokines as novel biomarkers and regulators of the metabolic syndrome. Ann NY Acad Sci 2010, 1212:E1-E19. 3075414, 21276002.
56. Tarek I, Tamimi AR, Elogouhari HM, Alkhouri N, Yerian M, Berk MP, Lopez R, Schauer PR, Zein NN, Feldstein AE. An apoptosis panel for nonalcoholic steatohepatitis diagnosis. J Hepatol 2011, 54:1224-1229. 10.1016/j.jhep.2010.08.023, 3098936, 21145805.
57. Younossi ZM, Jarrar M, Nugent C, Randhawa M, Afendy M, Stepanova M, Rafiq N, Goodman Z, Chandhoke V, Baranova A. A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH). Obes Surg 2008, 18:1430-1437. 10.1007/s11695-008-9506-y, 18500507.
58. Sookoian S, Castano G, Burgueno AL, Gianotti TF, Rosselli MS, Pirola CJ. A diagnostic model to differentiate simple steatosis from nonalcoholic steatohepatitis based on the likelihood ratio form of Bayes theorem. Clin Biochem 2009, 42:624-629. 10.1016/j.clinbiochem.2008.11.005, 19071103.
59. Sumida Y, Yoneda M, Hyogo H, Yamaguchi K, Ono M, Fujii H, Eguchi Y, Suzuki Y, Imai S, Kanemasa K, Fujita K, Chayama K, Yasui K, Saibara T, Kawada N, Fujimoto K, Kohgo Y, Okanoue T. Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD) A simple clinical scoring system using ferritin, fasting insulin, and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease. J Gastroenterol 2011, 46:257-268. 10.1007/s00535-010-0305-6, 20842510, Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD).
60. Younossi Z, Page S, Rafiq N, Birerdinc A, Stepanova M, Hossain N, Afendy A, Younoszai Z, Goodman Z, Baranova A. A biomarker panel for non-alcoholic steatohepatitis (NASH) and NASH-related fibrosis. Obes Surg 2011, 21:431-439. 10.1007/s11695-010-0204-1, 20532833.
61. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictor of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999, 30:1356-1362. 10.1002/hep.510300604, 10573511.
62. Ratziu V, Gira P, Charlotte F, Bruckert E, Thibault V, Theodorou I, Khalil L, Turpin G, Opolon P, Poynard T. Liver fibrosis in overweight patient. Gastroenterology 2000, 118:1117-1123. 10.1016/S0016-5085(00)70364-7, 10833486.
63. Rosenberg WM, Voelker M, Thiel R, Becka M, Burt A, Schuppan D, Hubscher S, Roskams T, Pinzani M, Atrhur MJ. European Liver Fibrosis Group Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 2004, 127:1704-1713. 10.1053/j.gastro.2004.08.052, 15578508, European Liver Fibrosis Group.
64. Guha IN, Parkes J, Rodreick P, Chattopadhyay D, Cross R, Harris S, Kaye P, Burt AD, Ryder SD, Aithal GP, Day CP, Rosenberg WM. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology 2008, 47:455-460.
65. Ratziu V, Massard J, Charlotte F, Messous D, Imbert-Bismut F, Bonyhay L, Tahiri M, Munteanu M, Thabut D, Cadranel JF, Le Bail B, de Ledinghen V, Poynard T. LIDO Study Group CYTO study group Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol 2006, 6:6. 10.1186/1471-230X-6-6, 1386692, 16503961, LIDO Study Group CYTO study group.
66. Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, Enders F, Saksena S, Burt AD, Bida JP, Lindor K, Sanderson SO, Lenzi M, Adams LA, Kench J, Therneau TM, Day CP. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007, 45:846-854. 10.1002/hep.21496, 17393509.
67. Harrison SA, Oliver D, Arnod HL, Gogia S, Neuschwander-Tetri BA. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut 2008, 57:1441-1447. 10.1136/gut.2007.146019, 18390575.
68. Cales P, Laine F, Boursier J, Deugnier Y, Moal V, Oberti F, Hunault G, Rousselet MC, Hubert I, Laafi J, Ducluzeaux PH, Lunel F. Comparison of blood tests for liver fibrosis specific or not to NAFLD. J Hepatol 2009, 50:165-173.
69. Shah A, Lydecker A, Murray K, Tetri BN, Contos MJ, Sanyal AJ. Nash Clinical Research Network Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009, 7:1104-1112. 10.1016/j.cgh.2009.05.033, 3079239, 19523535, Nash Clinical Research Network.
70. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American association for the study of liver diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012, 55:2005-2023. 10.1002/hep.25762, 22488764.
71. Younossi ZM, Baranova A, Ziegler K, Del Giacco L, Schlauch K, Born TL, Elariny H, Gorreta F, VanMeter A, Younoszai A, Ong JP, Goodman Z, Chandhoke V. A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease. Hepatology 2005, 42:665-674. 10.1002/hep.20838, 16116632.
72. Trak-Smayra V, Dargere D, Noun R, Albuquerque M, Yaghi C, Gannage-Yared MH, Bedossa P, Paradis V. Serum proteomic profiling of obese patients: correlation with liver pathology and evolution after bariatric surgery. Gut 2009, 58:825-832. 10.1136/gut.2007.140087, 18403495.
73. Bell LN, Theodorakis JL, Vuppalanchi R, Saxena R, Bemis KG, Wang M, Chalasani N. Serum proteomics and biomarker discovery across the spectrum of nonalcoholic fatty liver disease. Hepatology 2010, 51:111-120. 10.1002/hep.23271, 2903216, 19885878.
74. Charlton M, Viker K, Krishnan A, Sanderson S, Veldt B, Kaalsbeek AJ, Kendrick M, Thompson G, Que F, Swain J, Sarr M. Differential expression of lumican and fatty acid binding protein-1: new insights into the histologic spectrum of nonalcoholic fatty liver disease. Hepatology 2009, 49:1375-1384. 10.1002/hep.22927, 2674237, 19330863.
75. Rodriguez-Suarez E, Duce AM, Caballeria J, Arrieta FM, Fernandez E, Gomara C, Alkorta N, Ariz U, Martinez-Chantar ML, Lu SC, Elortza F, Mato JM. Non-alcoholic fatty liver disease proteomics. Proteomics Clin Appl 2010, 4:362-371. 10.1002/prca.200900119, 3040121, 21137056.
76. Younossi ZM, Varanova A, Stepanova M, Page S, Calvert VS, Afendy A, Goodman Z, Chandhoke V, Liotta L, Petricoin E. Phosphoproteomic biomarkers predicting histologic nonalcoholic steatohepatitis and fibrosis. J Proteome Res 2010, 9:3218-3224. 10.1021/pr100069e, 20441224.
77. Ulukaya E, Yilmaz Y, Moshkovskii S, Karpova M, Pyatnitskiy M, Atug O, Dolar E. Proteomic analysis of serum in patients with non-alcoholic steatohepatitis using matrix-assisted laser desorption ionization time-of-flight mass spectrometry. Scand J Gastroenterol 2009, 44:1471-1476. 10.3109/00365520903353379, 19883279.